Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

FOSAVANCE 70 MG/2.800 UI COMPRIMIDOS - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/FOSAVANCE 70 MG/2.800 UI COMPRIMIDOS

Approved

STANDARD

FOSAVANCE 70 MG/2.800 UI COMPRIMIDOS

Organon N.V.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Mar 12, 2024
Approval ID: f74c281ae2e9c2ea
Company: Organon N.V.
Type: Standard

Approval Details

Approval Id: f74c281ae2e9c2ea
Drug Cima Aemps Name: FOSAVANCE 70 MG/2.800 UI COMPRIMIDOS
Register Number: 05310002IP1
Holder Company Name: Organon N.V.
Marketing Company Name: Elam Pharma Labs S.L.
Authorization Date: 2024-03-12
Dosage Form: COMPRIMIDO
Dose: 70/2800 mg/UI
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: Yes
Company Name: Organon N.V.

Active Ingredients

ALENDRONICO ACIDO

70 mg

COLECALCIFEROL

70 µg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Mar 12, 2024

Approval ID

f74c281ae2e9c2ea

Type

Standard

Back to CIMA-AEMPS Approvals